WILSON'S DISEASE DEGENERATION

Wilson's disease, also called Wilson disease or hepatolenticular degeneration, is an autosomal recessive genetic disorder in which copper accumulates in tissues; this manifests as neurological or psychiatric symptoms and liver disease. It is treated with medication that reduces copper absorption or removes the excess copper from the body, but occasionally a liver transplant is required.[

The condition is due to mutations in the Wilson disease protein (ATP7B) gene. A single abnormal copy of the gene is present in 1 in 100 people, who do not develop any symptoms (they are carriers). If a child inherits the gene from both parents, the child may develop Wilson's disease. Symptoms usually appear between the ages of 6 and 20 years, but cases in much older people have been described. Wilson's disease occurs in 1 to 4 per 100,000 people. It is named after Samuel Alexander Kinnier Wilson (1878–1937), the British neurologist who first described the condition in 1912

Contact Details

IKRIS Pharma Network Pvt. Ltd.
905 , I - Thum Business Park,
Plot No. A-40, Unit No. 5, Tower A,
Sector-62, Noida – 201301 (India)

Phone No.- +91-120–2400370.
M: + 91 8130290915
E:info@ikrispharmanetwork.com

Query Form

WILSON'S DISEASE MEDICATIONS

Syprine (Trientine Hydrocloride)

SYPRINE is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with SYPRINE is limited and alternate dosing regimens have not been well-characterized;

More Details